Prescription Required.
Is the active ingredient.
Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Dabigo 75mg Cap (Dabigatran Etexilate) is a direct thrombin inhibitor. It works by preventing thrombin, a key enzyme in blood clotting, from forming blood clots.
Store at room temperature (20-25°C). Protect from moisture. Keep out of reach of children.
Dosage and administration vary depending on the indication and individual patient factors. Always follow your doctor's instructions.
The medication is usually taken orally, with or without food.
Bleeding (most common side effect, ranging from minor to severe).
Rare but serious side effects: allergic reactions, angioedema, and other rare complications.
Gastrointestinal issues (e.g., nausea, abdominal pain, dyspepsia).
Elevated liver enzymes.
Alcohol may increase the risk of bleeding. Consult your doctor regarding alcohol consumption while taking dabigatran.
Drowsiness or dizziness may occur; avoid driving or operating machinery if affected.
Use only if clearly needed under the guidance of a physician. Risk-benefit assessment crucial. Discuss with doctor.
Not recommended for use in children.
Dose adjustment may be necessary for patients with kidney impairment. Renal function should be monitored.
Dose adjustment may be necessary for patients with severe liver impairment. Liver function should be monitored.
Consult your physician or pharmacist for detailed information and references.
Check the official prescribing information for the specific brand of dabigatran etexilate.
